Publication Name	World Journal of Clinical Cases
Manuscript ID	90531
Country	China

Received	2023-12-07 14:40
Peer-Review Started	2023-12-07 14:40
To Make the First Decision
Return for Revision	2023-12-17 01:05
Revised	2023-12-26 14:59
Second Decision	2024-01-15 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-01-15 07:33
Articles in Press	2024-01-15 07:33
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-01-25 07:51
Publish the Manuscript Online	2024-01-31 06:42

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Editorial
Article Title	Strengthening pharmacotherapy research for COVID-19-induced pulmonary fibrosis
Manuscript Source	Invited Manuscript
All Author List	Yan-Miao Liu, Jing Zhang, Jing-Jing Wu, Wei-Wei Guo and Fu-Shan Tang
ORCID	Author(s) ORCID Number Yan-Miao Liu http://orcid.org/0009-0004-4553-8127 Jing Zhang http://orcid.org/0009-0003-2899-8474 Jing-Jing Wu http://orcid.org/0009-0008-1713-7624 Wei-Wei Guo http://orcid.org/0009-0001-0687-0934 Fu-Shan Tang http://orcid.org/0000-0001-8779-1041
Funding Agency and Grant Number	Funding Agency Grant Number Project of Special Funds for Science and Technology Cooperation in Guizhou Provinces and Zunyi City Shengshikehe (2015) 53
Corresponding Author	Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No.6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Key Words	COVID-19; Pulmonary fibrosis; Pharmacotherapy intervention; Medication administration; Timing; Dosage
Core Tip	Pulmonary fibrosis (PF) induced by coronavirus disease 2019 (COVID-19) represents a significant and serious complication of the disease. When PF advances to a critical stage, lung transplantation becomes the sole life-saving option. Our call is for an intensified focus on researching pharmacotherapy interventions for COVID-19-induced PF, aimed at identifying potential medication options.
Publish Date	2024-01-31 06:42
Citation	Liu YM, Zhang J, Wu JJ, Guo WW, Tang FS. Strengthening pharmacotherapy research for COVID-19-induced pulmonary fibrosis. World J Clin Cases 2024; 12(5): 875-879
URL	https://www.wjgnet.com/2307-8960/full/v12/i5/875.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i5.875

Full Article (PDF)	WJCC-12-875-with-cover.pdf
Full Article (Word)	WJCC-12-875.docx
Manuscript File	90531_Auto_Edited-YJP.docx
Answering Reviewers	90531-Answering reviewers.pdf
Audio Core Tip	90531-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90531-Conflict-of-interest statement.pdf
Copyright License Agreement	90531-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	90531-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	90531-Language certificate.pdf
Peer-review Report	90531-Peer-review(s).pdf
Scientific Editor Work List	90531-Scientific editor work list.pdf
CrossCheck Report	90531-CrossCheck report.pdf